GlobeNewswire

NYNJA Announces Plans for First Blockchain-Enabled International Messaging App with Integrated Digital Marketplace and its own Cryptocurrency Economy

Dela

Cross-platform App Enables Consumers and Enterprise Users to Communicate, Buy, Sell and Trade without Language Barriers in a Decentralized Cryptocurrency Marketplace

NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- NYNJA Group Ltd. (https://www.nynja.biz/), a global communications and mobile technology company, today announced NYNJA, the first international communications app with a built-in digital marketplace and cryptocurrency wallet. NYNJA is a cross-platform app that combines voice, text and visual messaging with robust and secure business management and e-commerce features, all powered by its own financial ecosystem and cryptocurrency, NYNJACoin. NYNJA, in development since Q1 2017, is currently in beta and the public token sale for NYNJACoin will launch on April 17, 2018.

"While there is no shortage of mobile messaging apps, there has never been an all-in-one communications app that seamlessly supports the messaging and transactional needs of both individual and business users with the utmost security protocols available today," said co-founder and CEO Salvatore Guerrieri. "NYNJA is the first app of its kind to harness the full potential of its user base, empowering them with a cross-platform multimedia messaging app and a built-in global marketplace backed by secure Blockchain protocols."

The NYNJA marketplace allows users to buy and sell goods and services internationally through an open API using NYNJACoin, the ERC20 standard cryptocurrency of NYNJA's integrated financial ecosystem. With NYNJACoin, users can also access exclusive groups and pay for proprietary in-group content such as licensed assets or timed consultations. Users can also earn NYNJACoin for viewing ads and sharing branded material like sticker-packs or coupons. Each account can be organized according to the user's social, consumer and business lives, and comes with a secure Ethereum wallet enabling users to transact freely within the app for fast international payment transfers without the need for costly external payment providers or internal platform fees. Completely scalable, the open-source platform will enable developers to build into NYNJA with the addition of value-add applications.

In addition to standard messaging features, NYNJA features scheduled messaging and translation. NYNJA is global, integrated and secure across every platform and device, and lets users make free Internet calls and transfer calls to any phone. NYNJA's architecture features secure encryption of cloud data storage for saving messages, images and files, and features a beautifully designed and intuitive interface highlighted by the app's patent-pending concentric wheel navigation system. The concentric wheel enables quick and easy navigation of the app using only one thumb and eliminates the use for back buttons.

"More than a quarter of the world uses mobile messaging apps, but the current class of apps falls short because they are either global but too basic, for example WhatsApp and Facebook Messenger, or have adoption limitations due to being region-specific as in the case of Line and WeChat," said NYNJA co-founder and president Alejandro Gramont. "Furthermore, many messaging apps are geared primarily for personal and social use rather than business; and most business-class apps lack the capabilities required to truly qualify them as enterprise-grade. NYNJA is in a class of its own as the only all-encompassing, highly customizable communications app with a blockchain-based marketplace and financial ecosystem."

At launch the NYNJA app will be available on Android, iOS, and Web with native development of Mac, Linux and Windows versions to follow.

NYNJA's experienced team includes CEO and global entrepreneur, Salvatore Guerrieri; co-founder, president and COO Alejandro Gramont; chief technology officer, Plamen Minev and co-founder and chief strategy officer Marshall Taplits. Advisors include Michael Terpin, CEO of investor conference series, CoinAgenda; Ken Lo, CEO of ANX International, which is a leading service provider of blockchain payment solutions; and Howard Bilton, founder of The Sovereign Group. Miles Pelham, founder of Digitas Limited and Mun Shing Cheong, the general manager of ANX Digital, are also advisors.

For more information about NYNJA Group Limited, please visit: https://www.nynja.biz/.

Learn more about the NYNJACoin ICO at https://nynjacoinusa.com/.

About NYNJA
NYNJA Group Limited is a Hong Kong-based company creating the first international cross-platform communications app with a built-in cryptocurrency marketplace and crypto wallet. The NYNJA app combines voice, text and visual messaging with robust business management and e-commerce features, all powered by its own financial ecosystem and cryptocurrency, NYNJACoin. With NYNJACoin, users can exchange freelance services and virtual goods, as well as access exclusive content and earn tokens for viewing ads or using branded material.

For more information on the NYNJA app and token sale, please visit: https://www.nynja.biz/.

Media Contact:

Transform Group, nynja@transform.pr  

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/8d324656-a32a-4b7a-8dfb-a09ebb3e719f




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NYNJA via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum